I
n the early 1980s, in their search for systems that import proteins into mitochondria, Yaffe and Schatz 1 identified a mutant in the yeast Saccharomyces cerevisiae, mas1 (mitochondrial assembly 1), that accumulates mitochondrial precursor proteins (Table) . In 1988, they cloned and sequenced the wildtype yeast MAS1 gene (systematic name: YLR163C), which encodes the catalytic subunit of the mitochondrial processing protease-a component of the mitochondrial import pathway and essential for cell viability. 2 Later, homologs of this gene were found in other eukaryotes, including humans, in which the gene was called PMPCB. 3 Around the same time, in 1986, a new gene was isolated from DNA of a human epidermoid carcinoma cell line, identified as a proto-oncogene, and named MAS. 4 Initially, the function of the MAS protein was unknown, and it was only in the early 2000s that it was identified as the GPCR (G-protein-coupled receptor) through which Ang (angiotensin)-(1-7) signals. Unfortunately, the MAS gene was later renamed by the HUGO (Human Genome Organisation) Human Gene Nomenclature Committee to MAS1 (full name: MAS1 proto-oncogene, GPCR), and also in mouse, rat, and all other tetrapods, it got the new name Mas1. Fortunately, MAS is still an accepted alias of the MAS1 proto-oncogene protein, and we will use this name in the following article to distinguish it from the yeast Mas1 protein. We would also like to suggest that the name MAS should be used in future publications. There is no homolog of MAS in any clade outside tetrapods. 5 However, several homologous genes were discovered in each tetrapod species, and the name MAS was given to this new family of receptors, the Mrgprs (Mas-related GPCRs). 5, 6 The duplication in nomenclature (Table) has unfortunately resulted in some misunderstandings and confusion in the Ang field because there are some papers that attribute Ang-(1-7) effects to yeast Mas1 protein. [8] [9] [10] [11] This may be especially important in the context of interpretation of results and consideration of tools used to interrogate mammalian MAS because it is likely that in some studies, antibodies to the yeast Mas1 protein rather than to the GPCR MAS may have been used erroneously. To further add to the complexity, the molecular size of the yeast Mas1 protein (~50 kDa) is not that dissimilar to that of human MAS (~40 kDa), and antibodies against MAS, which we tested, were nonspecific. 12 The confusion was additionally increased in 2016, when a putative thermostable lipase from a marine Streptomyces species was also named Mas1 (Table) . 13 However, at least until now, this protein has not been confused with MAS.
The aim of this brief review is to highlight the importance of discriminating between the different Mas1 proteins and to ensure that the GPCR MAS is indeed the protein of interest when examining Ang-(1-7) (patho)physiological actions. Here, we provide a historical overview of MAS and describe the origin of the name and how its functions have been unraveled.
Discovery of MAS as a Proto-Oncogene
The MAS gene was first identified in 1986 using an assay for human oncogenes based on their ability to induce tumorigenicity of NIH 3T3 cells in nude mice. 14, 15 Briefly, NIH 3T3 cells were cotransfected with DNA purified from a human tumor along with a G418 selectable marker. After selection and growth in culture, the G418-resistant cells were injected into nude mice. Several weeks later, DNA from tumors that formed in the mice was purified. The human DNA isolated from one of these tumors contained the MAS gene. The name MAS is an abbreviation of the last name (Massey) of the person who donated the human tumor from which the MAS gene was derived. This gene was cloned and shown to possess the ability to induce NIH 3T3 cells to form foci of transformed cells in culture and to form tumors in nude mice. 4 Therefore, MAS was called a proto-oncogene. However, MAS likely did not contribute to the formation of the human tumor because the gene did not appear to be rearranged or mutated in the original human tumor DNA; rather, the transforming potential of MAS in NIH 3T3 cells seemed to be activated by DNA rearrangement or amplification during transfection into NIH 3T3 cells. 4, 16 Moreover, recent findings have suggested that MAS activation by Ang-(1-7) could actually be a therapeutic target against tumors and has been suggested as a putative anticancer treatment.
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MAS as an Ang II Receptor
Already at the time of its discovery, the DNA sequence of the MAS gene was determined and shown to encode a protein with a 7-transmembrane domain structure similar to that of GPCR. 4 
Mas as an Imprinted Gene
In 1994, Mas was reported to be maternally imprinted in mice 29 and in human breast tissue, 30 that is, 1 of the 2 parental Mas alleles was epigenetically silenced. The Mas gene is located in close proximity to the imprinted Igf2r gene in the human and mouse genomes. 31, 32 Imprinting of this chromosomal area is regulated by an intronic control element starting the transcription of the long noncoding RNA, Airn (Antisense Igf2r RNA noncoding). The transcribed antisense RNA overlaps (and silences) the Igf2r promoter and partially the Mas gene. 33, 34 Using Mas-deficient mice, 35 we could show that Mas is biallelically expressed. 36 Because Villar and Pedersen 29 and Miller et al 30 used reverse-transcription-polymerase-chain reaction assays that lack strand selectivity to discover imprinting of Mas, it is very likely that they detected Airn as maternally imprinted RNA and not the Mas transcript. Thus, Airn but not Mas is monoallelically expressed in mouse and man.
MAS as an Ang-(1-7) Receptor
The first evidence for a receptor for Ang-(1-7) distinct from the Ang II receptors came from the observation that Ang-(1-7) was equipotent to Ang II for vasopressin release from hypothalamus-neurohypophyseal explants 37 but in contrast to Ang II had no effect on drinking behavior. 38 Moreover, Ang-(1-7) was reported to exert vasodilatory effects by releasing NO resulting in a blood pressure decrease. 39 This and other actions of Ang-(1-7), which all opposed the effects of Ang II, further supported that Ang-(1-7) mediates its effects through a novel non-AT 1 /AT 2 receptor subtype. The final proof for the existence of a specific receptor for the peptide was the discovery of a selective antagonist for Ang-(1-7) in 1994. 40, 41 Yet, it was only in 2003 that more definitive evidence for a specific binding site for Ang-(1-7) was demonstrated with the finding that MAS is a receptor for the heptapeptide. 42 In that study, specific binding of 125 I-Ang-(1-7) to Mastransfected cells was reported. Moreover, the specific binding of 125 I-Ang-(1-7) but not of 125 I-Ang II or 125 I-Ang IV to kidney sections was abolished by genetic deletion of Mas. In addition, Mas-deficient mice completely lack the antidiuretic action of Ang-(1-7) after an acute water load and Mas-deficient aortas lost their Ang-(1-7)-induced relaxation response. These findings provided the first clear molecular basis for the physiological actions of this biologically active peptide. At this point, an orphan receptor met an orphan peptide filling an important gap in our understanding of the reninAng system. Further support for these findings was obtained in different laboratories. In 2005, Tallant et al 43 showed that transfection of cultured myocytes with an antisense oligonucleotide to Mas blocked the Ang-(1-7)-mediated inhibition of serum-stimulated MAPK (mitogen-activated protein kinase) activation, whereas a sense oligonucleotide was ineffective. Ang-(1-7) was found to stimulate NO release and eNOS (endothelial NO synthase) activation in endothelial cells, and these effects were blocked by the specific MAS antagonist, A-779. 44, 45 In addition, Mas deficiency abolishes The rules for the nomenclature of genes and proteins differ between organisms. In humans (https://www.genenames.org/about/guidelines), both are in uppercase letters, and gene symbols are italicized. In rats and mice (http://www.informatics.jax.org/mgihome/nomen/gene.shtml#pon), only protein symbols are in uppercase letters, and gene symbols have only an initial uppercase letter and are also italicized. In yeast, gene symbols are in uppercase, italicized letters, and proteins are referred to by the relevant gene symbol, nonitalic, only initial letter uppercase, and with the suffix p, which can be omitted when the context reveals that the protein is meant (http://seq.yeastgenome.org/nomenclature-conventions). In bacteria, gene symbols are all in lowercase letters and italicized, protein names are nonitalic with only the first letter in uppercase. 7 Ang-(1-7) indicates angiotensin (1-7) ; GPCR, G-protein-coupled receptor; HGNC, HUGO Gene Nomenclature Committee; ID, identifier; MGI, Mouse Genome Informatics; NCBI, National Center for Biotechnology Information; and SGD, Saccharomyces Genome Database.
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all the known cardiovascular effects of Ang-(1-7). 46 Indeed, in most instances, genetic deletion of Mas causes alterations opposed to those produced by treatment with Ang- (1-7) .
Nevertheless, there are recent reports that Ang-(1-7) has no effect on MAS-transfected cells but exerts biased agonism or even antagonism at the AT 1 receptor. [47] [48] [49] Moreover, using other MAS agonists (neuropeptide FF and AR234960) and inverse agonists (AR244555), biased signaling of MAS itself was described. 50 Heteromeric interactions of MAS with AT 1 , AT 2 , bradykinin B2, and endothelin B receptors further complicate this issue. 27, 28, [51] [52] [53] Therefore, future studies need to clarify the relationship between MAS and Ang- (1-7) , which may depend on the specific cell types and their expression of other GPCRs. 54 
Conclusions
In conclusion, this brief review highlights important points related to some misconceptions and confusions on the nomenclature of MAS and its functions (Table) , especially in the context of cardiovascular pathophysiology. We suggest that the original name, Mas, is used for the GPCR. 
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